Pegylated Interferon-alpha (IFN)

PreclinicalSmall molecule

Pegylated Interferon-alpha (IFN) is one of 4 small molecule programs targeting Hepatitis B, Chronic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis B, ChronicRecruiting

Hepatitis B, ChronicPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Hepatitis B, Chronic

#DrugCompanyPhaseTrials

Bepirovirsen

GSK

Phase 2

1 2

AHB-137

AAusper Biopharma Co., Ltd.

Phase 2

3 3

PBGENE-HBV

PPrecision BioSciences, Inc.

Phase 1

1 4

Pegylated Interferon-alpha (IFN)

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Hepatitis B, Chronic

NCT06923280

Clinical

Trials by Indication[1]

Hepatitis C3 trials

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01358864·678 enrolled

Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00984620·160 enrolled

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment

Completed·KKarolinska Institutet·N/A·NCT00909129·25 enrolled

Hepatitis B, Chronic1 trial

Efficacy and Safety of Pegylated Interferon Therapy in Chronic Hepatitis B Patients After Discontinuation of Antisense Oligonucleotide or Small Interfering RNA: A Prospective, Adaptive, Open-label, Randomized Controlled Study

Recruiting·HHuashan Hospital·Preclinical·NCT06923280·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Pegylated Interferon-alpha (IFN). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegylated Interferon-alpha (IFN) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegylated Interferon-alpha (IFN). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Pegylated Interferon-alpha (IFN)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Hepatitis C3 trials

Hepatitis B, Chronic1 trial

References

Drug Info

Quick Facts

Related News